• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Nascent Biotech News

antibody-600
Nascent Biotech Research Partner, Manhattan BioSolutions, to Present at the ACCESS CHINA Forum at the 2021 JPMorgan Healthcare Conference

Nascent Biotech Research Partner, Manhattan BioSolutions, to Present at the ACCESS CHINA Forum at the 2021 JPMorgan Healthcare Conference

January 19, 2021  Corporate News, News, Press Releases

SAN DIEGO, CA / ACCESSWIRE / January 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO). Nascent Biotech Research Partner, Manhattan BioSolutions (MABS), Inc. announced that it will be presenting at [...]

0
Nascent Biotech Receives Full IND Clearance to Begin Phase I Human Trials for Brain Cancer

Nascent Biotech Receives Full IND Clearance to Begin Phase I Human Trials for Brain Cancer

December 15, 2020  Corporate News, News, Press Releases, Science News
Nascent Biotech Announces Promising Covid-19 Invitro Study Results with Syracuse University Collaboration

Nascent Biotech Announces Promising Covid-19 Invitro Study Results with Syracuse University Collaboration

October 20, 2020  Corporate News, News, Press Releases, Science News
Daily Orange: Professor researches antibody as possible treatment for COVID-19

Daily Orange: Professor researches antibody as possible treatment for COVID-19

October 14, 2020  Uncategorized
Nascent Biotech Continues to Reduce Liabilities by Over $2.0 Million Dollars

Nascent Biotech Continues to Reduce Liabilities by Over $2.0 Million Dollars

October 1, 2020  Corporate News, News, Press Releases
Load More

Delivering human antibodies for the treatment of cancer

© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.